Beam Therapeutics Inc.

08/04/2026 | Press release | Distributed by Public on 08/04/2026 05:04

Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
Beam Therapeutics Inc. published this content on August 04, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 04, 2026 at 11:10 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]